[HTML][HTML] BACE1 in the retina: a sensitive biomarker for monitoring early pathological changes in Alzheimer's disease
L Li, J Luo, D Chen, J Tong, L Zeng, Y Cao… - Neural Regeneration …, 2016 - journals.lww.com
Because of a lack of sensitive biomarkers, the diagnosis of Alzheimer's disease (AD) cannot
be made prior to symptom manifestation. Therefore, it is crucial to identify novel biomarkers
for the presymptomatic diagnosis of AD. While brain lesions are a major feature of AD,
retinal pathological changes also occur in patients. In this study, we investigated the
temporal changes in β-site APP-cleaving enzyme 1 (BACE1) expression in the retina and
brain to determine whether it could serve as a suitable biomarker for early monitoring of AD …
be made prior to symptom manifestation. Therefore, it is crucial to identify novel biomarkers
for the presymptomatic diagnosis of AD. While brain lesions are a major feature of AD,
retinal pathological changes also occur in patients. In this study, we investigated the
temporal changes in β-site APP-cleaving enzyme 1 (BACE1) expression in the retina and
brain to determine whether it could serve as a suitable biomarker for early monitoring of AD …